Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Manhattan Pharmaceuticals |
---|---|
Information provided by: | Manhattan Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00449254 |
Multi-center, multiple-dose, randomized, double-blind, three-arm, placebo-controlled study of fixed-dose repeated oral dosing for 30 days of 10 mg and 30 mg MP-101 and placebo in obese subjects.
Condition | Intervention | Phase |
---|---|---|
Obesity |
Drug: oleoyl-estrone (MP-101) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2a Randomized, Double-Blind, Placebo Controlled, Parallel Group, Safety and Efficacy Study of Oleoyl-Estrone (MP-101) in Male Obese Adults. |
Ages Eligible for Study: | 18 Years to 60 Years |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |
St. Luke's-Roosevelt Hospital | |
New York, New York, United States, 10025 | |
United States, Texas | |
Research Across America | |
Dallas, Texas, United States, 75234 | |
United States, Utah | |
Jean Brown Research | |
Salt Lake City, Utah, United States, 84124 |
Study ID Numbers: | MAN-OE-US-04 |
Study First Received: | March 16, 2007 |
Last Updated: | June 4, 2007 |
ClinicalTrials.gov Identifier: | NCT00449254 |
Health Authority: | United States: Food and Drug Administration |
Body Weight Signs and Symptoms Obesity Nutrition Disorders |
Overweight Overnutrition Oleoyl-estrone Estrone |
Anti-Obesity Agents Estrogens Therapeutic Uses Physiological Effects of Drugs |
Hormones, Hormone Substitutes, and Hormone Antagonists Central Nervous System Agents Hormones Pharmacologic Actions |